Entera Bio (NASDAQ:ENTX) Trading Down 2.1% – Here’s Why

Shares of Entera Bio Ltd. (NASDAQ:ENTX) traded down 2.1% during mid-day trading on Wednesday . The company traded as low as $2.70 and last traded at $2.81. Approximately 308,461 shares changed hands during trading, a decline of 94% from the average daily volume of 4,870,486 shares. The stock had previously closed at $2.87.

Analyst Ratings Changes

Several research firms recently weighed in on ENTX. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Entera Bio Trading Up 1.8%

The firm has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $1.48. The stock has a market cap of $141.46 million, a price-to-earnings ratio of -10.63 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, equities analysts expect that Entera Bio Ltd. will post -0.34 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Schonfeld Strategic Advisors LLC lifted its position in shares of Entera Bio by 5.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after buying an additional 29,629 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 338.4% in the 1st quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock worth $526,000 after purchasing an additional 365,441 shares during the last quarter. Seven Fleet Capital Management LP increased its position in shares of Entera Bio by 51.9% during the 1st quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock worth $228,000 after purchasing an additional 70,224 shares in the last quarter. Jane Street Group LLC lifted its holdings in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after purchasing an additional 43,536 shares during the last quarter. Finally, HighTower Advisors LLC lifted its holdings in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical?stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.